Results 231 to 240 of about 47,521 (285)

Nanobody–chlorin e6 conjugate for Nectin‐4‐mediated tumor targeting and enhanced photodynamic therapy

VIEW, EarlyView.
Nectin‐4 is frequently overexpressed in solid tumors, yet many PDT photosensitizers show poor water solubility and nonspecific uptake. A Nectin‐4‐targeted nanobody–chlorin e6 conjugate (NPC) improves aqueous solubility and selectively accumulates in Nectin‐4‐positive tumor cells.
Haodian Wan, Tao Ye, Yawei Bi, Jiayu Zhang, Wei Wu, Aochi Liu, Li Sun, Jie Lin, Ningli Chai, Manjie Zhang, Jian Ma   +10 more
wiley   +1 more source

FAP Expression in Renal Tumors Assessed by [⁶⁸Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients from the Prospective Exploratory Trial NCT04147494. [PDF]

J Nucl Med
Holzgreve A, Unterrainer LM, Flores K, Lam EC, Mona CE, Czernin J, Shuch BM, Sisk AE, Calais J.   +8 more
europepmc   +1 more source

Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
A phase IV, single‐arm, open‐label, multicenter study assessing the safety and efficacy of trastuzumab emtansine in Indian patients for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive unresectable locally advanced or metastatic breast cancer who received prior treatment with trastuzumab and a taxane.
Sudeep Gupta, Manish Singhal, Shona Nag, Waseem Abbas, Dinesh Chandra Doval, Hari Goyal, Chirag Shah, Ashish Singh, Radheshyam Naik, Nitesh Rohatgi, Poonam Patil, Shyam Aggarwal, Vinod Raina, Vaibhav Watts   +13 more
wiley   +1 more source

Engineered nanoconjugates for simultaneous detection and degradation of stroke-associated microthrombi. [PDF]

Theranostics
Picot A, Jacqmarcq C, Seillier C, de Lizarrondo SM, Gauberti M, Talukdar A, Khalin I, Mouriaux C, Mangin P, Goux D, Schmidt P, Vivien D, Bonnard T.   +12 more
europepmc   +1 more source

Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC)

Epilepsia, EarlyView.
Abstract Objective This randomized, double‐blind, phase 1b/2a clinical trial was designed to evaluate the safety, tolerability, and efficacy of oral bexicaserin versus placebo for the treatment of seizures in adolescents and adults with developmental and epileptic encephalopathies (DEEs).
Dennis J. Dlugos, Ingrid E. Scheffer, Jacqueline A. French, David G. Vossler, Chad Orevillo, Shikha Polega, Randall Kaye, and the LP352‐201 Study Investigators, Kore Liow, Ena Zhu, Jennifer Waldron, Hayley Groubert, Alexis Anderson, Pavel Klein, Salman Hashmi, Shicong Ye, Anita Farhi, David Vossler, Dione M. Froman, Shannon L. Hoffman‐Huffaker, Ki Hyeong Lee, AnnaLyn Dallas, Amir Arain, Laura Beeler, Michael Macken, Irena Bellinski, Elizabeth Cunningham, James Renfroe, Shezsay Colbert, Robert Hogan, Patty Schaefer, Susan Shaw, Sheetal Desai, Ahmed Sadek, Haile Robertson, Kamil Detyniecki, Anabela Cieslicki, Ruben Kuzniecky, Sarah Goodman, Selim Benbadis, Marina Azevedo, Sami Aboumatar, Julie Biel, Nilika Singhal, Emerald Wan, Evan Fertig, Hannah Hart, Debopam Samanta, Sarah Hankins, Steven Wolf, Patricia Pena, Robert Nahouraii, M. J. Mari, David Burdette, Stephanie Mueller, Karen Keough, Victoria Henderson, Talitha Durgin, Terence O’Brien, Rafael Smith, Jack Germaine, Kate Riney, Lori Anthony, David Reutens, Kimberley Irwin, Michael Fahey, Melissa Batt, Stephanie Kaladis, Kasthoori Jeyachanthiran, Ingrid Scheffer, Rebecca Wharrie, Greesha Zacharia, Brittany Walsh, Heather Robinson, Sharon Ganter   +74 more
wiley   +1 more source

An organolutetium nanosensitizer synergizes with PARP inhibition to unleash STING-mediated immunity for low-dose radioimmunotherapy. [PDF]

Theranostics
Zeng B, Ling K, Yuan Q, Chen Z, Zhang G, Kang W, Zheng X, Liao C, Mai Y, Huang Z, Huang R, Zhai T, Jiang H.   +12 more
europepmc   +1 more source

Cognitive stagnation and executive function deficits in young children with SCN1A+ Dravet syndrome: Detailed characterization of onset, progression, and impact in the ENVISION natural history study

Epilepsia, EarlyView.
Abstract Objective Dravet syndrome (DS) is a developmental and epileptic encephalopathy characterized by drug‐resistant seizures and developmental slowing. Although cognitive and executive function deficits have been described, their early trajectory is not well understood.
Joseph Sullivan, M. Scott Perry, Ingrid E. Scheffer, James Wheless, Susana Boronat, Andreas Brunklaus, Linda Laux, Anup D. Patel, Colin Roberts, Dennis Dlugos, Deborah Holder, Kelly Knupp, Matt Lallas, Steven Phillips, Eric Segal, Dennis Lal, Elaine Wirrell, Sameer Zuberi, Gerard Gioia, Rebecca Shaffer, Madison M. Berl, Mary Wojnaroski, Sarah Christensen, Alexander King, Emma S. James, Maria Candida Vila, Norman Huang, Jacqueline S. Gofshteyn, Salvador Rico   +28 more
wiley   +1 more source

PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions. [PDF]

Cancers (Basel)
Civelek AC.
europepmc   +1 more source

Matched Pair Theranostics.

Chimia, 2019
openaire   +2 more sources

Adjunctive Therapies in Periodontitis: Current Concepts and the Future

Journal of Periodontal Research, EarlyView.
This graphical abstract summarizes the translational pathway from preclinical research to clinical implementation of adjunctive therapies for periodontitis, highlighting key barriers, innovative therapeutic strategies, and emerging tools that aim to bridge experimental discoveries with patient care.
Rafael Scaf de Molon, Joao Paulo Steffens, Erica Dorigatti de Avila, Wim Teughels, Thomas E. Van Dyke   +4 more
wiley   +1 more source